Revelation Biosciences (NASDAQ:REVB) Shares Up 4.8% – Time to Buy?

Shares of Revelation Biosciences, Inc. (NASDAQ:REVB) were up 4.8% on Wednesday . The company traded as high as $1.11 and last traded at $1.09. Approximately 106,923 shares traded hands during mid-day trading, an increase of 155% from the average daily volume of 41,852 shares. The stock had previously closed at $1.04.

Wall Street Analyst Weigh In

Separately, Weiss Ratings upgraded Revelation Biosciences from a “sell (e)” rating to a “sell (e+)” rating in a report on Thursday, July 9th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock currently has a consensus rating of “Sell”.

Revelation Biosciences Stock Up 4.8%

The firm’s 50-day moving average is $1.03 and its 200-day moving average is $1.55. The company has a market cap of $4.26 million, a PE ratio of -0.03 and a beta of -0.12.

Revelation Biosciences (NASDAQ:REVB) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($2.71) EPS for the quarter, missing the consensus estimate of ($1.15) by ($1.56). As a group, equities research analysts anticipate that Revelation Biosciences, Inc. will post -4.99 EPS for the current fiscal year.

Hedge Funds Weigh In On Revelation Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC boosted its holdings in shares of Revelation Biosciences by 442.8% during the 4th quarter. Armistice Capital LLC now owns 434,272 shares of the company’s stock valued at $347,000 after buying an additional 354,272 shares in the last quarter. Sabby Management LLC lifted its position in Revelation Biosciences by 192.5% during the 4th quarter. Sabby Management LLC now owns 605,702 shares of the company’s stock valued at $484,000 after acquiring an additional 398,651 shares during the period. Finally, Geode Capital Management LLC bought a new stake in Revelation Biosciences during the fourth quarter worth about $27,000. Hedge funds and other institutional investors own 12.80% of the company’s stock.

About Revelation Biosciences

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.